Table 4 Treatment response and survival in the Phase II intention-to-treat population

From: Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

  Patients, N =54 % (95% CI)
Overall response rate
CR 0
PR 1 1.8
SD 34 63.0
PD 17 31.5
NE 2 3.7
DCR (PR+SD) 35 64.9 (51–77)
OS
Median, months (95% CI)   8 (4.8–9.7)
Rates 6 Months 58 (44–70)
  12 Months 26 (14–40)
  18 Months 13 (4–26)
PFS
Median, months (95% CI)   3.7 (3.2–4.7)
Rates 6 Months 28 (17–40)
  12 Months 3 (0–13)
  1. Abbreviations: CI=confidence interval; CR=complete response; DCR=disease control rate; NE=not evaluable; OS=overall survival; PD=progressive disease; PFS=progression-free survival; PR=partial response; SD=stable disease.